Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMBER: VAY736 in autoimmune hepatitis with inadequate response or intolerance to standard therapy
2017-001555-32Phase 2Active
- Sponsor
- Novartis
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ianalumab in autoimmune hepatitis (AIH) (3 arms), sponsored by Novartis. Primary endpoint: ALT normalization at Week 24 (Part 1). Started Oct 2017; status: active.
02
Drugs
ianalumab
03
Conditions
autoimmune hepatitis (AIH)
Beyond the preview
Go deeper on 2017-001555-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001555-32.